Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX)

Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 9, Stifel increased its price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) from $15 to $24 while keeping a Buy rating on the stock.

The firm pointed to recent progress in PRMT5 inhibitors and RAS(ON) combinations, which the firm believes lowers the risk for the company’s first-line pancreatic ductal adenocarcinoma opportunity. Stifel also included risk-adjusted first-line pancreatic ductal adenocarcinoma credit into its financial model for Tango Therapeutics, Inc. (NASDAQ:TNGX).

Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX)

Earlier, on March 5, Jefferies also increased its price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) from $14 to $18 and maintained its Buy rating on the stock.

Jefferies pointed to the company’s supply agreement with ERAS for pan-RAS. The research firm pointed out that upcoming topline data from Revolution Medicines on daraxonrasib, expected in the first half of 2026 for second-line pancreatic ductal adenocarcinoma, could set a new standard of care.

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a clinical-stage biotechnology company focused on the discovery of novel drug targets and the delivery of precision medicine for the treatment of cancer.

While we acknowledge the risk and potential of TNGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TNGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.